Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Guy M Goodwin, Scott T Aaronson, Oscar Alvarez...
https://pubmed.ncbi.nlm.nih.gov/36322843/Actively Recruiting
Led by Tel-Aviv Sourasky Medical Center · Updated on 2026-07-30
13
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to assess the safety, tolerability, and preliminary clinical effects of psilocybin-enhanced trauma-focused psychotherapy in adults with post-traumatic stress disorder PTSD. PTSD is a chronic condition with symptoms like intrusive memories, avoidance, mood changes, and hyperarousal. Despite existing treatments, many patients do not find sufficient relief, so this pilot study explores a new approach combining psilocybin, a psychedelic compound, with trauma-focused therapy based on Acceptance and Commitment Therapy and Narrative Exposure Therapy. Participants undergo a structured treatment including preparatory psychotherapy sessions, followed by two oral psilocybin dosing sessions 15 mg first, then 25 mg administered in a controlled clinical setting with medical supervision. Each dosing session lasts about six hours, after which integration psychotherapy sessions help process trauma and incorporate insights. The study physician monitors safety throughout and can stop dosing if needed. The study includes a total of 13 participants to gather preliminary data for future research. During the study, participants receive clinical evaluations, symptom assessments using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5, and safety monitoring from dosing through 30 days after completing therapy. Adverse events and tolerability are tracked as primary outcomes, while changes in PTSD symptom severity serve as secondary measures. Participants attend multiple therapy sessions and remain in clinical care during dosing, with follow-up visits to evaluate lasting effects and ensure safety.
CONDITIONS
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD
A
Ayelet Or-Borichev, PhD
J
Jackob Nimrod Keynan, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tel-Aviv Sourasky Medical Center
Lead Sponsor
Tel Aviv University Sagol School of Neuroscience
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits
Duration - Several weeks
Participants receive preparatory psychotherapy sessions, two psilocybin dosing sessions (15 mg then 25 mg) with medical monitoring, and six integration psychotherapy sessions focusing on trauma processing.
Multiple therapy and dosing sessions
Duration - 30 days
Participants are monitored for safety and assessed for changes in PTSD symptoms up to 30 days after completing the treatment sessions.
Follow-up assessments during this period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Guy M Goodwin, Scott T Aaronson, Oscar Alvarez...
https://pubmed.ncbi.nlm.nih.gov/36322843/Brandon Neisewander, Christopher Moreau
https://pubmed.ncbi.nlm.nih.gov/39504448/Jennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk...
https://pubmed.ncbi.nlm.nih.gov/37709999/Matthew W Johnson, Roland R Griffiths
https://pubmed.ncbi.nlm.nih.gov/28585222/Collin M Reiff, Elon E Richman, Charles B Nemeroff...
https://pubmed.ncbi.nlm.nih.gov/32098487/Maria M Steenkamp, Brett T Litz, Charles W Hoge...
https://pubmed.ncbi.nlm.nih.gov/26241600/Tel-Aviv Sourasky Medical Center
Lead Sponsor
Tel Aviv University Sagol School of Neuroscience
Collaborating Sponsor